Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 5/20 | 0.44 |
| ▸ | NMT2 | O60551 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.42 |
| ▸ | FURIN | P09958 | 6/20 | 0.42 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31668833 | 0.96 | FURIN (0.43) | OPRL1NMT2NMT1FURINPDCD1LG2 | |
| SCHEMBL30445587 | 0.86 | NMT1 (0.47) | OPRL1NMT2NMT1FURINOPRM1 | |
| SCHEMBL29630669 | 0.85 | FURIN (0.47) | NMT2NMT1FURINPDCD1LG2CD274 | |
| SCHEMBL30902091 | 0.83 | NMT2 (0.42) | OPRL1NMT2NMT1FURIN | |
| SCHEMBL29973308 | 0.82 | PDCD1LG2 (0.48) | PDCD1LG2CD274OPRM1OPRD1 | |
| SCHEMBL29854499 | 0.82 | CD274 (0.52) | PDCD1LG2CD274OPRM1OPRD1 | |
| SCHEMBL30445612 | 0.81 | NMT1 (0.49) | NMT2NMT1 | |
| SCHEMBL30828464 | 0.81 | FOLH1 (0.48) | NMT2NMT1 | |
| SCHEMBL29822483 | 0.81 | CCNA2 (0.40) | OPRL1NMT2NMT1 | |
| SCHEMBL31031501 | 0.80 | NMT1 (0.44) | OPRL1NMT2NMT1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195687-A1 | PEPTIDE-BASED PHOSPHATE BINDER FOR THE TREATMENT OF HYPERPHOSPHATEMIA | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD. (IL) | 2025-06-19 | — | — | US | disclosed |